Cargando…

Cardioprotective effects of Cu((II))ATSM in human vascular smooth muscle cells and cardiomyocytes mediated by Nrf2 and DJ-1

Cu((II))ATSM was developed as a hypoxia sensitive positron emission tomography agent. Recent reports have highlighted the neuroprotective properties of Cu((II))ATSM, yet there are no reports that it confers cardioprotection. We demonstrate that Cu((II))ATSM activates the redox-sensitive transcriptio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Srivastava, Salil, Blower, Philip J., Aubdool, Aisah A., Hider, Robert C., Mann, Giovanni E., Siow, Richard C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431352/ https://www.ncbi.nlm.nih.gov/pubmed/28442712 http://dx.doi.org/10.1038/s41598-016-0012-5

Ejemplares similares

Modification of intracellular glutathione status does not change the cardiac trapping of (64)Cu(ATSM)
por: Shaughnessy, Fiona, et al.
Publicado: (2014)

Cu(II)(atsm) Attenuates Neuroinflammation
por: Choo, Xin Yi, et al.
Publicado: (2018)

Tissue acidosis does not mediate the hypoxia selectivity of [(64)Cu][Cu(ATSM)] in the isolated perfused rat heart
por: Baark, Friedrich, et al.
Publicado: (2019)

(64)Cu-ATSM and (18)FDG PET uptake and (64)Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry
por: Hansen, Anders E, et al.
Publicado: (2012)

The anti‐ageing hormone klotho induces Nrf2‐mediated antioxidant defences in human aortic smooth muscle cells
por: Maltese, Giuseppe, et al.
Publicado: (2016)

Cellular Uptake of the ATSM−Cu(II) Complex under Hypoxic Conditions
por: Walke, Gulshan R., et al.
Publicado: (2021)

CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits
por: Vieira, Fernando G., et al.
Publicado: (2017)

Validation of (64)Cu-ATSM damaging DNA via high-LET Auger electron emission
por: McMillan, Dayton D., et al.
Publicado: (2015)

Does the ATSM-Cu(II) Biomarker Integrate into the Human Cellular Copper Cycle?
por: Walke, Gulshan R., et al.
Publicado: (2019)

(64)Cu-ATSM/(64)Cu-Cl(2) and their relationship to hypoxia in glioblastoma: a preclinical study
por: Pérès, Elodie A., et al.
Publicado: (2019)

TRPA1 is essential for the vascular response to environmental cold exposure
por: Aubdool, Aisah A., et al.
Publicado: (2014)

Dose painting based on tumor uptake of Cu-ATSM and FDG: a comparative study
por: Clausen, Malene Martini, et al.
Publicado: (2014)

Pharmacokinetic Analysis of (64)Cu-ATSM Dynamic PET in Human Xenograft Tumors in Mice
por: Li, Fan, et al.
Publicado: (2015)

Assessment of the Tumor Redox Status in Head and Neck Cancer by (62)Cu-ATSM PET
por: Tsujikawa, Tetsuya, et al.
Publicado: (2016)

Focus on the Controversial Aspects of (64)Cu-ATSM in Tumoral Hypoxia Mapping by PET Imaging
por: Colombié, Mathilde, et al.
Publicado: (2015)

(64)Cu-ATSM internal radiotherapy to treat tumors with bevacizumab-induced vascular decrease and hypoxia in human colon carcinoma xenografts
por: Yoshii, Yukie, et al.
Publicado: (2017)

Development of an automated production process of [(64)Cu][Cu (ATSM)] for positron emission tomography imaging and theranostic applications
por: Liu, Tengzhi, et al.
Publicado: (2022)

Transient receptor potential canonical 5 (TRPC5) protects against pain and vascular inflammation in arthritis and joint inflammation
por: Alawi, Khadija M, et al.
Publicado: (2017)

Impact of [(64)Cu][Cu(ATSM)] PET/CT in the evaluation of hypoxia in a patient with Glioblastoma: a case report
por: Gangemi, Vincenzo, et al.
Publicado: (2019)

(64)Cu-ATSM Predicts Efficacy of Carbon Ion Radiotherapy Associated with Cellular Antioxidant Capacity
por: Nachankar, Ankita, et al.
Publicado: (2021)

Pre-clinical Positron Emission Tomography Reconstruction Algorithm Effect on Cu-64 ATSM Lesion Hypoxia
por: Sanghera, Bal, et al.
Publicado: (2016)

Hypoxia imaging and theranostic potential of [(64)Cu][Cu(ATSM)] and ionic Cu(II) salts: a review of current evidence and discussion of the retention mechanisms
por: Liu, Tengzhi, et al.
Publicado: (2020)

Vascular protection afforded by zinc supplementation in human coronary artery smooth muscle cells mediated by NRF2 signaling under hypoxia/reoxygenation
por: Yang, Fan, et al.
Publicado: (2023)

DJ-1 administration exerts cardioprotection in a mouse model of acute myocardial infarction
por: Gallinat, Alex, et al.
Publicado: (2022)

64Cu-ATSM Hypoxia Positron Emission Tomography for Detection of Conduit Ischemia in an Experimental Rat Esophagectomy Model
por: Park, Seong Yong, et al.
Publicado: (2015)

Assessment of hypoxia and oxidative-related changes in a lung-derived brain metastasis model by [(64)Cu][Cu(ATSM)] PET and proteomic studies
por: Fantin, Jade, et al.
Publicado: (2023)

Monte Carlo Evaluation of Dose Enhancement Due to CuATSM or GNP Uptake in Hypoxic Environments with External Beam Radiation
por: Martinez, Stephen, et al.
Publicado: (2020)

Cerebral Oxidative Stress in Early Alzheimer’s Disease Evaluated by (64)Cu-ATSM PET/MRI: A Preliminary Study
por: Okazawa, Hidehiko, et al.
Publicado: (2022)

Hyperglycemia-Induced Inhibition of DJ-1 Expression Compromised the Effectiveness of Ischemic Postconditioning Cardioprotection in Rats
por: Liu, Min, et al.
Publicado: (2013)

The hypoxia imaging agent Cu(II)(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson’s disease
por: Hung, Lin W., et al.
Publicado: (2012)

Nrf2-regulated redox signaling in brain endothelial cells adapted to physiological oxygen levels: Consequences for sulforaphane mediated protection against hypoxia-reoxygenation
por: Warpsinski, Gabriela, et al.
Publicado: (2020)

Gene dysregulation is restored in the Parkinson’s disease MPTP neurotoxic mice model upon treatment of the therapeutic drug Cu(II)(atsm)
por: Cheng, Lesley, et al.
Publicado: (2016)

Multiple Administrations of (64)Cu-ATSM as a Novel Therapeutic Option for Glioblastoma: a Translational Study Using Mice with Xenografts
por: Yoshii, Yukie, et al.
Publicado: (2017)

Preclinical Pharmacokinetic and Safety Studies of Copper-Diacetyl-Bis(N(4)-Methylthiosemicarbazone) (Cu-ATSM): Translational Studies for Internal Radiotherapy
por: Matsumoto, Hiroki, et al.
Publicado: (2019)

Feasibility of Renal Blood Flow Measurement Using (64)Cu-ATSM PET/MRI: A Quantitative PET and MRI Study
por: Nishikawa, Yudai, et al.
Publicado: (2023)

Cu(ATSM) Increases P-Glycoprotein Expression and Function at the Blood-Brain Barrier in C57BL6/J Mice
por: Pyun, Jae, et al.
Publicado: (2023)

Evaluation of hypoxia in a feline model of head and neck cancer using (64)Cu-ATSM positron emission tomography/computed tomography
por: Ballegeer, Elizabeth A, et al.
Publicado: (2013)

ET-7 EVALUATION OF HYPOXIA-TARGETING RADIOPHARMACEUTICAL(64)CU-ATSM FOR PET MONITORING WITH LOCAL THERAPY IN HIGH-GRADE GLIOMA MODEL
por: Yoshii, Yukie, et al.
Publicado: (2022)

CuATSM effectively ameliorates ALS patient astrocyte‐mediated motor neuron toxicity in human in vitro models of amyotrophic lateral sclerosis
por: Dennys, Cassandra N., et al.
Publicado: (2022)

Protein deglycase DJ‐1 deficiency induces phenotypic switching in vascular smooth muscle cells and exacerbates atherosclerotic plaque instability
por: Wang, Zhao‐yang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cbsa5mpjtvspdfhqh2gd45lv1p